SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Committee for Medicinal Products for Human Use (CHMP) Confirms Original Opinion on Santhera Pharmaceuticals AG's SNT-MC17/Idebenone for Treatment of Friedreich's Ataxia